Shares of Sarepta Mar 13, 2018 Sarepta Therapeutics, Inc. Sarepta Therapeutics Inc. 9 Oct 2017 Controversy over data quality took the shine off Sarepta's U. By Alex Keown. S. insurer Anthem, Inc. Sep 6, 2017 Sarepta Therapeutics reports positive results from a clinical trial of an experimental medicine for Duchenne muscular dystrophy. 6 Sep 2017 Sarepta's Doug Ingram responds to a question about the high cost for a drug for Duchenne muscular dystrophy. Food And Drug Administration 7 Sep 2017 Sarepta is preparing to file a follow-up to its Duchenne muscular dystrophy (DMD) treatment Exondys 51 that seems to have greater efficacy. Kesselheim, associate professor at Harvard Medical School, is quoted. Eteplirsen also called AVI-4658, is a drug designed for treatment, but not a cure, of some . (SRPT - Get Report) is under fire from patient groups that backed the Food and Drug Administration approval of its FDA panel rejects Sarepta drug to treat Duchenne muscular dystrophy. The company Mar 12, 2018 Sarepta Therapeutics will file an application with the Food and Drug Administration by the end of 2018 seeking accelerated approval for its Sep 6, 2017 Sarepta's Doug Ingram responds to a question about the high cost for a drug for Duchenne muscular dystrophy. Mar 12, 2018 Sarepta Therapeutics says regulators at the Food and Drug Administration have told it they were open to reviewing its next experimental Sep 29, 2017 Shares of Sarepta are falling today following reports of the deaths of three patients using its Duchenne muscular dystrophy drug. May 4, 2018 CHMP Rejects Sarepta's DMD Drug, Company Strikes Gene Therapy Deal with Myonexus Therapeutics. a lift, agreeing to cover the biotech's Duchenne muscular dystrophy 12 Mar 2018 Sarepta Therapeutics says regulators at the Food and Drug Administration have told it they were open to reviewing its next experimental In addition to our FDA-approved treatment for Duchenne muscular dystrophy, we are developing a variety of drug candidates based on our proprietary Learn about clinical trials for our leading drug candidate, eteplirsen, (for DMD), as well as programs for influenza and Marburg hemorrhagic fever. The U. (SRPT) faces fresh competition for Duchenne Muscular Dystrophy treatment. Feb 10, 2017 Sarepta Therapeutics Inc. Aaron S. 13 Mar 2018 Sarepta Therapeutics will file an application with the Food and Drug Administration by the end of 2018 seeking accelerated approval for its . SRPT announced that it will seek rapid approval for its second drug, golodirsen, to treat Duchenne Muscular May 7, 2018 US drugmaker Sarepta Therapeutics last revealed that it has received a negative trend vote following its European Medicines Apr 5, 2018 Nonprofits Urge HHS To Take Over Sarepta's Exondys Patents “Given the orphan drug exclusivity for Exondys 51, the stronger measures are Sep 19, 2016 The US Food and Drug Administration (FDA) on Monday approved Sarepta Therapeutics' first drug to treat patients with Duchenne muscular Nov 13, 2017 Major U. Sep 7, 2017 Sarepta shares surged as much as 14% on hopes that a new Duchenne muscular dystrophy drug could get faster-than-normal approval. approval of Duchenne muscular dystrophy drug Exondys51 last year. Sarepta and the patient groups wanted to use the standard of historical controls, personal testimonies, and the presence of altered dystrophin in the In addition to our FDA-approved treatment for Duchenne muscular dystrophy, we are developing a variety of drug candidates based on our proprietary Learn about clinical trials for our leading drug candidate, eteplirsen, (for DMD), as well as programs for influenza and Marburg hemorrhagic fever. has given biotech Sarepta Therapeutics Inc. Now the 6 Sep 2017 REUTERS: Sarepta Therapeutics Inc's shares jumped about 15 percent on Wednesday after the company's drug to treat patients with a form of 12 Mar 2018 Like Sarepta's first approved drug, golodirsen works by skipping over a genetic mutation that causes Duchenne muscular dystrophy in some 29 Sep 2017 Sarepta Therapeutics (SRPT) flopped Friday after the Food and Drug Administration released details of patient deaths following treatment with 6 Apr 2018 Sarepta Therapeutics Inc. 26 Oct 2017 Sarepta Therapeutics' (SRPT) drug for Duchenne muscular dystrophy (DMD) that launched last year is helping patients with the disease, 20 Jul 2017 Sarepta Therapeutics' drug for Duchenne muscular dystrophy (DMD) is gaining traction and that could continue to lift its shares even after a 7 Sep 2017 Sarepta shares surged as much as 14% on hopes that a new Duchenne muscular dystrophy drug could get faster-than-normal approval. Food And Drug Administration Mar 13, 2018 Sarepta Therapeutics will file an application with the Food and Drug Administration by the end of 2018 seeking accelerated approval for its Mar 13, 2018 Read about how Sarepta Therapeutics is planning to file an NDA with the FDA for their second DMD drug. on Wednesday released promising 10 Feb 2017 Sarepta Therapeutics Inc. Sarepta and the patient groups wanted to use the standard of historical controls, personal testimonies, and the presence of altered dystrophin in the 12 Mar 2018 Sarepta Therapeutics will file an application with the Food and Drug Administration by the end of 2018 seeking accelerated approval for its 6 Sep 2017 Sarepta Therapeutics says its new DMD drug helps patients produce the crucial protein dystrophin, but it's unclear whether that boosts muscle 6 Sep 2017 One the FDA's biggest controversies is coming back to test its new leadership